ALSO READShilpa Medicare gets EIR from USFDA for Jadcherla facility Shilpa Medicare spurts as USFDA accepts corrective action plan Shilpa Medicare gets EIR from USFDA for Raichur facilities Shilpa Medicare consolidated net profit declines 0.69% in the March 2017 quarter Shilpa Medicare standalone net profit rises 23.45% in the March 2017 quarter
From USFDAShilpa Medicare announced that the US FDA has issued an Establishment Inspection Report (EIR) for the Company's generic pharmaceutical manufacturing facility at Jadcherla in Telangana, India which was inspected between 24 and 28 July 2017. The inspection has now been closed by the US FDA. The Company had submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines in response to the form 483 issued at the end of inspection. The US FDA has reviewed the CAPA and has found them acceptable.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)